Ondine Biomedical Secures Interim CEO Funding
Company Announcements

Ondine Biomedical Secures Interim CEO Funding

Ondine Biomedical, Inc. (GB:OBI) has released an update.

Ondine Biomedical Inc. has announced that CEO Carolyn Cross provided the company with a C$285,000 loan for additional working capital, with no interest or set repayment terms. The funding from the founding shareholders, who own 49.5% of the company, is to support Ondine while it seeks longer-term financing, expected to be secured in Q4. Ondine specializes in photodisinfection technology and is moving towards regulatory approval for its Steriwave nasal photodisinfection system in the US.

For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Secures C$16.2 Million for US Trials
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Inc. Launches £8.5 Million Fundraise
TipRanks UK Auto-Generated NewsdeskOndine Biomedical Inc. Secures Interim Funding Boost
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App